Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Please do more homework this stock is getting ready to explode!
This is possible because most of the legalities and government requirements have already been met by the public shell, having gone public some time before the reverse merger. At the end of the merger those in charge of the private company gain control of the public shell’s shares, and both companies’ shares are merged into one, with the private company becoming public.
In addition to taking less time and legal footwork to undergo, a public shell reverse merger can be better because most of the merged company’s shares are of course held by the company, meaning the shares can be sold for a large amount of capital to recover for the costs of the merger. The reverse merger is also less expensive than a regular IPO, for a number of reasons, such as not needing an underwriting company to complete the action.
A reverse merger is usually called a public shell reverse merger. In this kind of a merger, a public shell merges with a private company, allowing the private company to begin making public securities offerings. The management of the private company is enabled to take control over almost all of the public shell’s controlling interest—the company’s shares—and the board of directors. The public shell—a company that has no operating history, no assets, and no liabilities—is merged into a by private company. Such a reverse merger is a good alternative to making an Initial Public Offering (IPO).
A public shell reverse merger consumes much less time than an IPO (IPO’s can last months, but a public shell reverse merger can be completed in a few weeks). This is possible because most of the legalities and government requirements have already been met by the public shell, having gone public some time before the reverse merger. At the end of the merger those in charge of the private company gain control of the public shell’s shares, and both companies’ shares are merged into one, with the private company becoming public.
In addition to taking less time and legal footwork to undergo, a public shell reverse merger can be better because most of the merged company’s shares are of course held by the company, meaning the shares can be sold for a large amount of capital to recover for the costs of the merger. The reverse merger is also less expensive than a regular IPO, for a number of reasons, such as not needing an underwriting company to complete the action.
EXCELLENT POST!
This is very good news!
It's old news, but it' hidden news. Elite's not official release/announce yet!
NICE!!
See you all at .30 in 10 hours!
Buying more!
Sorry you guys feel that way but I believe news is news. No matter which way you look at it! Anyways this not the only news will be hearing . This is the beginning of many big things to come!
NEWS APRIL 16 2011... (ELTP) Elite Pharmaceuticals Inc. Leads Weekly Top 10 as Technicals Poised to Move Stock this Coming Week. http://wallstreetpanel.com/pennystock/otc-penny-stocks-showing-powerful-trends-for-next-week-sney-rppr-ghlv-cpow-and-kblb/
WOW! GOOD NEWS!
How many times he has told us sometimes he uses iPhone and it's not that easy to type . I'm on one right now!
This is good news for us all!
See you all over .10 NICE FIND!!!
Doing very good work,Thanks!
OVER .30 here we come!
NEWS!!!!!!
NEWS!!
NEWS!!!!
NEWS................................................................
CHECK IT OUT VERY COOL!
It will and it's coming this is just a start very excited!
From the 8-K: "TPN made a cash payment of $500,000 to Elite. As part of the Settlement Agreement, TPN also acknowledges that the Company may develop a generic product containing methadone of any strength (including the filing of an abbreviated new drug application relating to such product) and that nothing in the Settlement Agreement restricts the Company from developing, commercializing, manufacturing and distributing any pharmaceutical product similar to, or which may compete with, the Product or the ANDA filed in connection with the Product."
So, ELTP can continue developing, manufacturing, commercializing these products. This agreement is good for both ELTP and TPN; and the lawsuit between them was officially dismissed.
2011-02-03
Purchase 2011-03-17
08:02 am ELITE PHARMACEUTICALS INC ELTP POTTI RAM
(Director
10% owner) 407,949 $0.04 $16,318 497,949
(Direct) View
2011-02-02
Purchase 2011-03-17
07:58 am ELITE PHARMACEUTICALS INC ELTP NIGALAYE ASHOK G
(Chief Scientific Officer
Director
10% owner) 407,949 $0.04 $16,318 407,949
(Direct) View
2011-02-03
Purchase 2011-03-16
9:53 pm ELITE PHARMACEUTICALS INC ELTP TREPPEL JERRY
(Chairman & CEO
Director) 587,834 $0.04 $23,513 1,691,893
(Direct) View
2011-02-03
Purchase 2011-03-16
9:29 pm ELITE PHARMACEUTICALS INC ELTP NARINE JEENARINE
(Director
10% owner) 407,949 $0.04 $16,318 407,949
(Direct) View
2011-02-03
Purchase 2011-03-16
9:12 pm ELITE PHARMACEUTICALS INC ELTP Dash Barry H
(Director) 340,954 $0.04 $13,638 377,066
(Direct) View
2011-02-03
Purchase 2011-03-16
8:48 pm ELITE PHARMACEUTICALS INC ELTP DICK CHRIS
(President & COO
Director) 426,192 $0.04 $17,048 451,000
(Direct) View
2011-02-03
Purchase 2011-03-16
8:39 pm ELITE PHARMACEUTICALS INC ELTP Ward Carter Julian
(Chief Financial Officer) 426,192 $0.04 $17,048 426,192
(Direct) View
2011-02-03
Purchase 2011-03-16
8:26 pm ELITE PHARMACEUTICALS INC ELTP WHITNELL JEFFREY A
(Director) 340,954 $0.04 $13,638 340,954
(Direct) View
Nice to see insiders buying up all this stock!
So what are you saying we'll be lucky enough to see .10
Got a feeling where about to be hearing something really good.
As disclosed by Hi-Tech Pharmacal, ECR Pharmaceutical initiated in 2010 a formal approval process with the FDA regarding Lodrane® 24 and Lodrane® 24D and ECR will continue to actively pursue approval for both products.